CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer...
Phase 2
San Francisco, California, United States and 8 other locations
avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...
Phase 2
San Francisco, California, United States and 11 other locations
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
San Francisco, California, United States and 166 other locations
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
San Francisco, California, United States and 199 other locations
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO)...
Phase 2
Palo Alto, California, United States and 13 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
San Francisco, California, United States and 228 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
San Francisco, California, United States and 108 other locations
after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...
Phase 2
San Francisco, California, United States and 121 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Santa Rosa, California, United States and 505 other locations
The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...
Phase 3
San Francisco, California, United States and 140 other locations
Clinical trials
Research sites
Resources
Legal